Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Clinical Trial to Evaluate the Effects of NB1111 in Patients with either Glaucoma or Underlying Ocular Hypertension

Next Previous
Trial Profile

A Phase IIa Clinical Trial to Evaluate the Effects of NB1111 in Patients with either Glaucoma or Underlying Ocular Hypertension

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 10 Jun 2024 According to a Skye Bioscience media release, the company to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program.
  • 10 Jun 2024 Status changed from planning to discontinued, according to a Skye Bioscience media release.
  • 21 Aug 2023 According to a Skye Bioscience media release, company is preparing to initiate a Phase 2a study in glaucoma in Q4 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top